Free Trial
→ Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad)

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 11 of 15

Slide 11
Back to 10
Continue to 12
 
Back to 10
Continue to 12
 

Jazz Pharmaceuticals (NASDAQ:JAZZ)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
11 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$173.14 (60.9% Upside)

About Jazz Pharmaceuticals

Jazz Pharmaceuticals logoJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/4/2024Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$174.00 ➝ $175.00
9/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$205.00 ➝ $205.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00
8/19/2024JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$190.00 ➝ $202.00
8/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00
8/1/2024Piper SandlerLower Price TargetOverweight ➝ Overweight$188.00 ➝ $166.00
8/1/2024Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$175.00 ➝ $174.00
8/1/2024Wells Fargo & CompanyLower Price TargetEqual Weight ➝ Equal Weight$140.00 ➝ $120.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
8/1/2024Needham & Company LLCLower Price TargetBuy ➝ Buy$208.00 ➝ $205.00
Slide 11
Back to 10
Continue to 12
 

Next opportunity for crypto millions (Ad)

The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine…

Go here to discover the crypto that's about to leave Wall Street in the dust.

More From MarketBeat
What Is the $7,882 Stimulus Payment 2024?
Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...
Angel Publishing | Sponsored
7 Defense Stocks That Don’t Need the Election to Move Higher
The defense sector is a good place for investors who are looking for both growth and value. While it's not one...
MarketBeat
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
7 High-Yield Dividend Stocks to Beat Fixed-Income Yields
Fixed-income investments have been making a comeback. After nearly 10 consecutive years of the Federal Reserve...
MarketBeat
$20 = Ounce of Gold?
I've discovered a way to get exposure to MORE than an ounce of gold... for under $20. It's not bullion. It'...
Monument Traders Alliance | Sponsored
7 Consumer Discretionary Stocks Just Waiting for a Rate Cut
Consumer discretionary stocks have been a fairly predictable trade over the last five years. In 2020 and 2021,...
MarketBeat